-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80

Benzinga·09/15/2026 13:21:28
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.